Journal of Blood & Lymph

What We are Learning from Real World Data on Rivaroxaban for the Treatment of VTE: An Overview

Abstract

Pierpaolo Di Micco, Francesco Dentali, Nicola Mumoli, Matteo Giorgi Pierfranceschi, Maria Amitrano, Fulvio Pomero Giorgio Vescovo, Gualberto Gussoni, Daniela Mastroiacovo and Andrea Fontanella

Rivaroxaban is one of most common used DOACs in the treatment of VTE. Rivaroxaban has been tested in a series of premarketing studies and after it has been used in non-interventional studies and in real life studies.
All studies experienced that rivaroxaban shows relevant safety concerning main outcomes of VTE therapy as recurrent VTE and major bleedings, in particular in patients that show similar clinical characteristics to those selected for EINSTEIN studies. Suggested doses of rivaroxaban seem to be safe also in real life studies while non-conventional doses may be associated to increased rate of clinical complications as recurrent VTE and major bleedings. Rivaroxaban shows also good safety when used in real life studies in patients with clinical characteristics that differ from those of patients in the EINSTEIN studies.